{
 "companyname": "SUNESIS PHARMACEUTICALS INC",
 "symbol": "SNSS",
 "description": "Pharmaceutical Preparations",
 "quarters": [
  {
   "cik": "0001061027",
   "companyname": "SUNESIS PHARMACEUTICALS INC",
   "entityid": 376501,
   "primaryexchange": "Nasdaq Capital Market",
   "primarysymbol": "SNSS",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "11/5/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "9/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 3,
   "dcn": "0001564590-15-009661",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": 368000,
   "changeincurrentliabilities": -2566000,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": 0,
   "cashfromfinancingactivities": 592000,
   "cashfrominvestingactivities": 5555000,
   "cashfromoperatingactivities": -9648000,
   "cfdepreciationamortization": 33000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 5555000,
   "netchangeincash": -3501000,
   "totaladjustments": -2627000,
   "ebit": -8570000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 683000,
   "incomebeforetaxes": -7021000,
   "interestexpense": -233000,
   "netincome": -7021000,
   "netincomeapplicabletocommon": -7021000,
   "researchdevelopmentexpense": 5259000,
   "totalrevenue": 683000,
   "sellinggeneraladministrativeexpenses": 3994000,
   "commonstock": 8000,
   "deferredcharges": null,
   "cashandcashequivalents": 16801000,
   "cashcashequivalentsandshortterminvestments": 30503000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": null,
   "othercurrentassets": null,
   "othercurrentliabilities": 0,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": null,
   "propertyplantequipmentnet": 17000,
   "retainedearnings": -547795000,
   "totalassets": 31316000,
   "totalcurrentassets": 31299000,
   "totalcurrentliabilities": 16144000,
   "totalliabilities": 19258000,
   "totallongtermdebt": 1893000,
   "totalreceivablesnet": null,
   "totalshorttermdebt": 5861000,
   "totalstockholdersequity": 12058000,
   "treasurystock": null
  },
  {
   "cik": "0001061027",
   "companyname": "SUNESIS PHARMACEUTICALS INC",
   "entityid": 376501,
   "primaryexchange": "Nasdaq Capital Market",
   "primarysymbol": "SNSS",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "7/30/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "6/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 2,
   "dcn": "0001564590-15-005869",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": 313000,
   "changeincurrentliabilities": 887000,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": 0,
   "cashfromfinancingactivities": 7969000,
   "cashfrominvestingactivities": 1755000,
   "cashfromoperatingactivities": -8206000,
   "cfdepreciationamortization": 42000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 1755000,
   "netchangeincash": 1518000,
   "totaladjustments": 743000,
   "ebit": -10623000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 854000,
   "incomebeforetaxes": -8949000,
   "interestexpense": -233000,
   "netincome": -8949000,
   "netincomeapplicabletocommon": -8949000,
   "researchdevelopmentexpense": 6302000,
   "totalrevenue": 854000,
   "sellinggeneraladministrativeexpenses": 5175000,
   "commonstock": 7000,
   "deferredcharges": null,
   "cashandcashequivalents": 20302000,
   "cashcashequivalentsandshortterminvestments": 39556000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": null,
   "othercurrentassets": null,
   "othercurrentliabilities": 1765000,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": null,
   "propertyplantequipmentnet": 19000,
   "retainedearnings": -540774000,
   "totalassets": 40740000,
   "totalcurrentassets": 40721000,
   "totalcurrentliabilities": 18284000,
   "totalliabilities": 23559000,
   "totallongtermdebt": 4421000,
   "totalreceivablesnet": null,
   "totalshorttermdebt": 3253000,
   "totalstockholdersequity": 17181000,
   "treasurystock": null
  },
  {
   "cik": "0001061027",
   "companyname": "SUNESIS PHARMACEUTICALS INC",
   "entityid": 376501,
   "primaryexchange": "Nasdaq Capital Market",
   "primarysymbol": "SNSS",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "5/5/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "3/31/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 1,
   "dcn": "0001564590-15-003315",
   "currencycode": "USD",
   "crosscalculated": false,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -259000,
   "changeincurrentliabilities": -4322000,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": 0,
   "cashfromfinancingactivities": 8411000,
   "cashfrominvestingactivities": -212000,
   "cashfromoperatingactivities": -11601000,
   "cfdepreciationamortization": 55000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": -212000,
   "netchangeincash": -3402000,
   "totaladjustments": -2473000,
   "ebit": -8769000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 854000,
   "incomebeforetaxes": -9128000,
   "interestexpense": -239000,
   "netincome": -9128000,
   "netincomeapplicabletocommon": -9128000,
   "researchdevelopmentexpense": 4512000,
   "totalrevenue": 854000,
   "sellinggeneraladministrativeexpenses": 5111000,
   "commonstock": 7000,
   "deferredcharges": null,
   "cashandcashequivalents": 18784000,
   "cashcashequivalentsandshortterminvestments": 39793000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": null,
   "othercurrentassets": null,
   "othercurrentliabilities": 3632000,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": null,
   "propertyplantequipmentnet": 31000,
   "retainedearnings": -531825000,
   "totalassets": 41302000,
   "totalcurrentassets": 41271000,
   "totalcurrentliabilities": 15919000,
   "totalliabilities": 24509000,
   "totallongtermdebt": 6881000,
   "totalreceivablesnet": null,
   "totalshorttermdebt": 713000,
   "totalstockholdersequity": 16793000,
   "treasurystock": null
  }
 ]
}